Los Angeles, USA, March 10, 2021 (GLOBE NEWSWIRE) -- Presbyopia Pipeline Analysis: Emerging Therapies Continue to Transform Clinical Landscape of Presbyopia
Presbyopia pipeline majorly includes the companies and their emerging pipeline drugs for the treatment of presbyopia.
DelveInsight’s ‘Presbyopia Pipeline Insights’ report provides a holistic view of the pipeline therapies that are under development in pre-clinical as well as clinical stages of development, and growth prospects across the Presbyopia domain.
The report lays down a complete coverage of the therapeutics by development stage, product type, route of administration, molecule type, and MOA type for Presbyopia across the complete product development cycle, including all clinical and non-clinical stages.
The Presbyopia pipeline report brings to the eye business opportunities, threats, prospective collaborations, strong competitors, growth strategies, and failed as well as discontinued drugs.
Some of the key highlights of the Presbyopia Pipeline report:
- Presbyopia Pipeline report offers a comprehensive analysis of 10+ key pharma players and 10+key pipeline therapies.
- Key companies dedicated to advance the Presbyopia drug pipeline are Cellix Bio, AbbVie, Novartis, Visus Therapeutics, AbbVie, Allergan, Encore Vision, Ocuphire Pharma, Orasis Pharmaceuticals, Eyenovia, and among others.
- Out of all the emerging therapies, UNR844-Cl (lipoic acid choline ester) is expected to emerge as the trendsetter owing to its ability to breaks disulfide bonds, which are thought to harden the lens over time. By disrupting these bonds, the lens becomes more elastic and regains some functionality.
- Presbyopia pipeline comprises CLX-OPH-561 (Cellix Bio) in the preclinical stage, while AGN 241622 (Abbvie) is in Phase I/II and UNR844-Cl (Novartis) and VTI-001 (Visus Therapeutics) in Phase II stage of development.
- In the late-stage of development, Abbvie is investigating its AGN-190584.
- In August 2020, Eyenovia entered into an exclusive license agreement with Arctic Vision to develop and commercialize MicroPine (Atropine micro formulation) and MicroLine (pilocarpine micro formulation) in China, Hong Kong, Macau and Taiwan and South Korea.
- In February 2021, Allergan submitted a New Drug Application to the Food and Drug Administration for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the NDA by the end of 2021.
Got queries? Want to know more? Request for Sample @ Presbyopia Pipeline Insights
Presbyopia is an age-related condition that results in a progressive loss of the ability to see nearby objects clearly. It usually gets noticed around the age of 40. It occurs either due to the weakening of the ciliary muscles or diminishing flexibility of the eye lens due to old age. Presbyopia is diagnosed by a basic refraction assessment of the eye and an eye health exam.
At the moment, no cure exists for presbyopia. The aim of the treatment is to make up for the loss and the inability of the eyes to focus on nearby objects. Wearing corrective eyeglasses (spectacle lenses) or contact lenses, undergoing refractive surgery, or getting lens implants for presbyopia are the only available treatments.
Presbyopia Pipeline Drug Profiles
UNR844-Cl: Novartis
UNR844-Cl is an ester of naturally occurring R-lipoic acid and choline. Previously called EV06 ophthalmic solution, UNR844 targets directly the flexibility and accommodative ability of the crystalline lens. It breaks disulfide bonds, which are thought to harden the lens over time. By disrupting these bonds, the lens becomes more elastic and regains some functionality.
Currently, Novartis is gearing up to run a phase 2b dose-finding study based on the results of phase 1 and 2a studies. The company plans further clinical development of UNR844-Cl, a topical ophthalmic solution for treating presbyopia.
For more information on emerging drugs, visit Presbyopia Pipeline Analysis
Presbyopia Pipeline Drugs
| Drug | Company | Clinical Phase | MoA | RoA | Expected Launch |
| CLX-OPH-561 | Cellix Bio | Pre-clinical | NA | NA | NA |
| AGN 241622 | AbbVie | I/II | Alpha 2 adrenergic receptor agonists | Topical | NA |
| UNR844-Cl | Novartis | II | Antioxidants; Free-radical scavengers | Topical | NA |
| VTI-001 | Visus Therapeutics | II | Alpha 2 adrenergic receptor agonists; Cholinergic receptor agonists | Topical | NA |
| AGN-190584 | AbbVie | Pre-registration | Muscarinic receptor agonists | Topical | NA |
Scope of the Report
Coverage: Global
Key Players: Cellix Bio, AbbVie, Novartis, Visus Therapeutics, AbbVie, Ocularis Pharma, among others.
Key Presbyopia Pipeline Therapies: CLX-OPH-561, UNR844-Cl, VTI-001, AGN-190584, Nyxol, PRX 100, among others.
Reach out @ Presbyopia Pipeline: Novel Therapies and Emerging Technologies
Table of Contents
| 1 | Introduction |
| 2 | Executive Summary |
| 3 | Presbyopia Overview |
| 4 | Presbyopia Pipeline Therapeutics |
| 5 | Presbyopia Pipeline Therapeutic Assessment |
| 6 | Presbyopia – DelveInsight’s Analytical Perspective |
| 7 | In-depth Commercial Presbyopia Pipeline Assessment |
| 8 | Presbyopia Collaboration Deals |
| 9 | Late Stage Presbyopia Pipeline Products (Phase III and Preregistration) |
| 10 | Mid-Stage Presbyopia Pipeline Products (Phase II) |
| 11 | Pre-clinical and Discovery Stage Presbyopia Pipeline Products |
| 12 | Inactive Presbyopia Pipeline Products |
| 13 | Presbyopia Key Companies |
| 14 | Presbyopia Key Products |
| 15 | Presbyopia Unmet Needs |
| 16 | Presbyopia Market Drivers and Barriers |
| 17 | Presbyopia Future Perspectives and Conclusion |
| 18 | Presbyopia Pipeline Analyst Views |
| 20 | Appendix |
Visit to know more of what’s covered @ Presbyopia Emerging Therapies
Related Reports
Presbyopia Market
DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2030" report.
Hay Fever Conjunctivitis Market
DelveInsight's "Hay Fever Conjunctivitis Market Insights, Epidemiology, and Market Forecast-2030" report.
Keratoconus Market
DelveInsight’s ‘Keratoconus (KC) Market Insights, Epidemiology and Market Forecast– 2030’ report.
Mantle Cell Lymphoma Market
DelveInsight's "Mantle Cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2030" report.
Meniere’s Disease Market
DelveInsight's "Meniere's Disease Market Insights, Epidemiology, and Market Forecast-2030" report.
Mydriasis Market
DelveInsight’s ‘Mydriasis Market Insights, Epidemiology, and Market Forecast-2030’ report.
Myopia Market
DelveInsight's "Myopia Market Insights, Epidemiology, and Market Forecast-2030" report.
Ocular Inflammation and Pain Market
DelveInsight's "Ocular Inflammation and Pain Market Insights, Epidemiology, and Market Forecast-2030" report.
Ptosis Market
DelveInsight's "Ptosis Market Insights, Epidemiology, and Market Forecast-2030" report.
Retinal Vein Occlusion Market
DelveInsight’s ‘Retinal Vein Occlusion—Market Insights, Epidemiology, and Market Forecast–2030’ report.
Retinitis Pigmentosa Market
DelveInsight's "Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2030" report.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.